Loading…
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $761M | - | $100M | $142M | 15.4% | 12.8% | -29.4% |
| 2024 | $675M | - | $141M | $196M | 20.8% | 39.9% | 33.0% |
| 2023 | $482M | - | $106M | $127M | 20.9% | 20.0% | 4.7% |
| 2022 | $402M | $116M | $101M | $120M | 20.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 401.86 | 482.38 | 675.04 | 761.41 |
| Operating Revenue | - | 401.86 | 482.38 | 675.04 | 761.41 |
| Cost Of Revenue | - | 5.38 | 6.48 | 10.88 | 12.98 |
| Gross Profit | - | 396.47 | 475.89 | 664.16 | 748.43 |
| Operating Expense | - | 283.84 | 368.61 | 527.21 | 703.63 |
| Research And Development | - | 130.99 | 184.35 | 246.89 | 254.91 |
| Selling General And Administration | - | 152.85 | 184.26 | 280.32 | 448.72 |
| Total Expenses | - | 289.22 | 375.09 | 538.09 | 716.61 |
| Operating Income | - | 112.63 | 107.28 | 136.95 | 44.80 |
| Total Operating Income As Reported | - | 112.63 | 107.28 | 136.95 | 44.80 |
| EBITDA | 127.95 | 116.08 | - | - | - |
| Normalized EBITDA | - | 116.08 | 109.64 | 138.29 | 46.69 |
| EBIT | - | 112.63 | 107.28 | 136.95 | 44.80 |
| Interest Income | - | 3.56 | 17.27 | 24.54 | 21.67 |
| Net Interest Income | - | 3.56 | 17.27 | 24.54 | 21.67 |
| Interest Income Non Operating | - | 3.56 | 17.27 | 24.54 | 21.67 |
| Net Non Operating Interest Income Expense | - | 3.56 | 17.27 | 24.54 | 21.67 |
| Pretax Income | - | 116.19 | 124.56 | 161.49 | 66.46 |
| Tax Provision | - | 14.77 | 18.42 | 20.28 | -33.19 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | 101.42 | 106.14 | 141.21 | 99.65 |
| Net Income From Continuing And Discontinued Operation | - | 101.42 | 106.14 | 141.21 | 99.65 |
| Net Income From Continuing Operation Net Minority Interest | - | 101.42 | 106.14 | 141.21 | 99.65 |
| Net Income | - | 101.42 | 106.14 | 141.21 | 99.65 |
| Net Income Common Stockholders | - | 101.29 | 105.50 | 139.73 | 98.17 |
| Net Income Including Noncontrolling Interests | - | 101.42 | 106.14 | 141.21 | 99.65 |
| Normalized Income | - | 101.42 | 106.14 | 141.21 | 99.65 |
| Diluted NI Availto Com Stockholders | - | 101.29 | 105.50 | 139.73 | 98.17 |
| Basic Average Shares | - | 106.79 | 103.56 | 103.23 | 103.86 |
| Diluted Average Shares | - | 115.97 | 111.74 | 113.48 | 119.99 |
| Reconciled Depreciation | - | 3.45 | 2.36 | 1.34 | 1.89 |
| Reconciled Cost Of Revenue | - | 5.38 | 6.48 | 10.88 | 12.98 |
| Total Unusual Items | 0 | 0 | 0 | 0 | - |
| Total Unusual Items Excluding Goodwill | 0 | 0 | 0 | 0 | - |
| Special Income Charges | 0 | 0 | 0 | 0 | - |
| Otherunder Preferred Stock Dividend | - | 0.13 | 0.64 | 1.48 | 1.48 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Corcept Therapeutics Incorporatedthis co. | CORT | $8.0B | 80.68↑ premium | 12.41 | 15.4% | 66.11 |
| Krystal Biotech, Inc. | KRYS | $9.1B | 44.30 | 7.44 | 16.8% | 51.16 |
| Charles River Laboratories International, Inc. | CRL | $8.9B | - | 2.83 | -4.6% | 27.52 |
| Henry Schein, Inc. | HSIC | $8.7B | 21.84 | 2.68 | 12.3% | 12.42 |
| Bio-Techne Corporation |
| 2021 |
| - |
| $128M |
| - |
| - |
| - |
| - |
| - |
| TECH |
| $8.3B |
| 113.50 |
| 4.34 |
| 3.8% |
| 39.69 |
| Alkermes plc | ALKS | $7.2B | 29.92 | 3.97 | 13.3% | 20.89 |
| Glaukos Corporation | GKOS | $7.1B | -38.08 | 10.89 | -28.6% | -49.02 |
| Protagonist Therapeutics, Inc. | PTGX | $6.6B | -50.79 | 10.75 | -21.2% | -41.39 |
| TG Therapeutics, Inc. | TGTX | $6.2B | 13.88 | 9.58 | 69.0% | 47.51 |
| Peer Median | - | 21.84 | 5.89 | 8.0% | 24.20 | |